Literature DB >> 680397

Cell-mediated immunity and postexposure protection from rabies by inactivated vaccines of tissue culture origin.

T J Wiktor.   

Abstract

A strong cell-mediated cytotoxic response (CMC), which was maximal 6-7 days after treatment, was generated in mice exposed to inactivated rabies virus vaccine. CMC response was linear and was a function of antigenic mass. Live attenuated viruses also generated a strong CMC response after intracerebral infection. Mice lethally infected with virulent strains of virus failed to develop CMC. There was, however, no difference in the rate and amount of virus-neutralizing or lytic antibodies and interferon induction in mice infected with virulent as compared to those infected with attenuated strains of virus. The level of T-cell effector function was found to be directly correlated with survival. Secondary CMC response to inactivated virus vaccine is strong, appears faster (3 days)and requires a smaller amount of antigen than does the primary CMC response. A consistent high level of CMC can be maintained for extended periods of time by repeated vaccine inoculations. When mice were treated with vaccine after being infected with street virus, high levels of CMC were found in effectively protected animals, but no CMC was found in unprotected animals. High levels of virus-neutralizing antibody were present in both surviving and dying mice. CMC responses to different antigenic components of rabies virus were also investigated.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 680397

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  8 in total

1.  Comparison of human immune responses to purified Vero cell and human diploid cell rabies vaccines by using two different antibody titration methods.

Authors:  P M Kitala; K J Lindqvist; E Koimett; B K Johnson; C N Chunge; P Perrin; O Olsvik
Journal:  J Clin Microbiol       Date:  1990-08       Impact factor: 5.948

2.  Overexpression of cytochrome C by a recombinant rabies virus attenuates pathogenicity and enhances antiviral immunity.

Authors:  R Pulmanausahakul; M Faber; K Morimoto; S Spitsin; E Weihe; D C Hooper; M J Schnell; B Dietzschold
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  Cells with natural killer activity in human rabies.

Authors:  T Panpanich; T Hemachudha; S Piyasirisilp; S Manatsathit; H Wilde; P Phanuphak
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

4.  Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene.

Authors:  T J Wiktor; R I Macfarlan; K J Reagan; B Dietzschold; P J Curtis; W H Wunner; M P Kieny; R Lathe; J P Lecocq; M Mackett
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

5.  Rabies virus stimulates nitric oxide production and CXC chemokine ligand 10 expression in macrophages through activation of extracellular signal-regulated kinases 1 and 2.

Authors:  Kazuo Nakamichi; Satoshi Inoue; Tomohiko Takasaki; Kinjiro Morimoto; Ichiro Kurane
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

6.  Recognition of rabies and rabies-related viruses by T cells derived from human vaccine recipients.

Authors:  E Celis; D Ou; B Dietzschold; H Koprowski
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

7.  Recovery of immune responsiveness to rabies vaccine after treatment of mice with cyclophosphamide.

Authors:  G S Turner
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

8.  An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs.

Authors:  Margit Schnee; Annette B Vogel; Daniel Voss; Benjamin Petsch; Patrick Baumhof; Thomas Kramps; Lothar Stitz
Journal:  PLoS Negl Trop Dis       Date:  2016-06-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.